Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Stem Cells

Manuscript NO: 64663

Title: Bone marrow mononuclear cells for joint therapy: the role of macrophages in inflammation resolution and tissue repair.

Reviewer's code: 05844467
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer's Country/Territory: Japan
Author's Country/Territory: United States

Manuscript submission date: 2021-02-21
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-02-24 07:53
Reviewer performed review: 2021-02-26 06:41
Review time: 1 Day and 22 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The authors investigated bone marrow mononuclear cells for joint therapy. This manuscript is valuable because the role of macrophages benefit patients.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Stem Cells

Manuscript NO: 64663

Title: Bone marrow mononuclear cells for joint therapy: the role of macrophages in inflammation resolution and tissue repair.

Reviewer's code: 05866841
Position: Peer Reviewer
Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-02-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-02-21 23:55

Reviewer performed review: 2021-02-26 23:10

Review time: 4 Days and 23 Hours

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [ ] Anonymous [Y] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

It is a well-written review that summarizes the current knowledge of bone marrow mononuclear cells for OA therapy. A few minor comments are listed below for further consideration. 1. Full gene nomenclatures should be provided at the first appearance instead of later. 2. It is better to detail the percentage of synovial macrophages and synovial fibroblasts if possible. 3. Some citations have formatting issues. A bibliography managing software, such as Endnote, is highly recommended. 4. Since the authors commented that '…it only makes sense to capitalize on the macrophage-mediated effects of BMNC to re-establish mechanisms of joint homeostasis to develop a targeted OA therapy,' it will be beneficial to briefly comment on the reason(s) why the current/future investigation on focusing on the BMNC instead of purified macrophages and macrophage progenitors from the bone marrow, especially when considering the accumulating evidence that suggests mesenchymal stem cells post a (pro)tumorigenic risk.